top of page

Stealth BioTherapeutics investigates SBT-272 to treat mitochondrial dysfunction in ALS

SBT-272, in the pipeline at Stealth BioTherapeutics, is a new peptidomimetic being investigated as a potential therapy for neurodegenerative illnesses that are associated with mitochondrial dysfunction. In preclinical experiments, the administration of SBT-272 to defective mitochondria led to an increase in the generation of adenosine triphosphate (ATP) and a decrease in the levels of reactive oxygen species (ROS). In comparison to elamipretide, Stealth’s first-in-class lead chemical, SBT-272 exhibits much higher mitochondrial uptake, significantly higher concentrations in the brain, and significantly enhanced oral bioavailability.

Stealth BioTherapeutics ( Stealth ), announced May of 2018 that the US Food and Drug Administration (FDA) Office of Orphan Products Development granted Orphan Drug Designation to the investigational drug candidate, elamipretide, for the treatment of Leber’s hereditary optic neuropathy (LHON).

In a mouse model of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease characterized by the deterioration of motor neurons and the atrophy of muscle tissue, treatment with SBT-272 was associated with a dose-dependent delay in the onset of neurological disease, a reduction in systemic markers of neurodegeneration, and a prolonged lifespan. ALS is one of the most common forms of neurodegenerative disease. The compound is presently being investigated in a further preclinical model of amyotrophic lateral sclerosis (ALS), as well as in a preclinical model indicative of activity in multiple system atrophy (MSA). MSA is a neurological condition that can result in parkinsonism, cerebellar ataxia, dysautonomia, and other motor and non-motor symptoms. It is thought that mitochondrial dysfunction has a role in the course of neurodegenerative disorders such as ALS and MSA, as well as other conditions such as Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease.

12 views0 comments

Recent Posts

See All

TVALA Drug Trial

We are happy to announce the first patients are being screened for entry into the clinical trial for our drug TVALA! This Phase 1 study will wrap up in a few months and the Phase 2 will start, it will

Thymosin in the treatment of lung cancer

A new paper authored by Liu and Lu in the Frontiers in Immunology reports the Mechanism and clinical application of thymosin in the treatment of lung cancer. Thymosin is a mixture of peptides obtained


We are hopeful that TVALA will reduce p53 expression in people with ALS. There are two recent publications that give us hope. The first paper is by Maor-Nof et. al. (2022), found in Cell. The found


Commenting has been turned off.
bottom of page